Understanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study

被引:3
作者
Assassi, Shervin [1 ]
Shao, Nan [2 ]
Yin, Ziwei [2 ]
Volkmann, Elizabeth R. [3 ]
Zoz, Donald F. [2 ]
Leonard, Thomas B. [2 ]
机构
[1] Univ Texas McGovern Med Sch, Div Rheumatol, 6431 Fannin St, Houston, TX 77030 USA
[2] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA
关键词
administrative claims; delayed diagnosis; healthcare; pulmonary fibrosis; scleroderma; systemic; IDIOPATHIC PULMONARY-FIBROSIS; CLASSIFICATION; MANAGEMENT; CRITERIA; UPDATE; DEATH;
D O I
10.1097/MD.0000000000029993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is usually detected in a patient known to have SSc but may be diagnosed prior to SSc. We probed an insurance database to investigate documentation of ILD prior to SSc. Using Optum's Clinformatics (R) Data Mart Database, we identified patients with an SSc index date between January 1, 2010, and September 30, 2015, based on International Classification of Diseases (ICD)-9-Clinical Modification (CM) codes, >= 2 medical claims associated with SSc on different dates within 1 year, and >= 3 years of continuous enrollment prior to SSc index date (ICD-9-CM cohort). We identified an ICD-10-CM cohort comprising patients with an SSc index date between October 1, 2017, and June 30, 2019, based on ICD-10-CM codes, >= 2 medical claims associated with SSc on different dates within 1 year, and >= 2 years of continuous enrollment prior to SSc index date. ILD was defined as >= 2 medical claims associated with ILD on different dates. The ICD-9-CM and ICD-10-CM cohorts comprised 1779 and 1032 patients, respectively. In these cohorts, respectively, 7.6% and 9.3% of patients had their second medical claim associated with ILD prior to their SSc index date, and 4.3% and 5.6% of patients had their second medical claim associated with ILD >1 year prior to the SSc index date. In this analysis, 4% to 6% of patients with SSc had claims for ILD >1 year prior to a claim for SSc. These data show that SSc can affect the lung early and demonstrate the importance of screening patients with SSc for ILD and patients with ILD for SSc.
引用
收藏
页数:5
相关论文
共 36 条
  • [1] Callejas-Moraga Eduardo Luis, 2019, Clin Exp Rheumatol, V37 Suppl 119, P41
  • [2] The impact of rheumatological evaluation in the management of patients with interstitial lung disease
    Castelino, Flavia V.
    Goldberg, Hilary
    Dellaripa, Paul F.
    [J]. RHEUMATOLOGY, 2011, 50 (03) : 489 - 493
  • [3] Interstitial lung disease:: are we missing formes frustes of connective tissue disease?
    Cottin, V.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (05) : 893 - 896
  • [4] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Distler, Oliver
    Highland, Kristin B.
    Gahlemann, Martina
    Azuma, Arata
    Fischer, Aryeh
    Mayes, Maureen D.
    Raghu, Ganesh
    Sauter, Wiebke
    Girard, Mannaig
    Alves, Margarida
    Clerisme-Beaty, Emmanuelle
    Stowasser, Susanne
    Tetzlaff, Kay
    Kuwana, Masataka
    Maher, Toby M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (26) : 2518 - 2528
  • [5] Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis
    Distler, Oliver
    Allanore, Yannick
    Denton, Christopher P.
    Matucci-Cerinic, Marco
    Pope, Janet E.
    Hinzmann, Barbara
    Davies, Siobhan
    Pena, Janethe de Oliveira
    Khanna, Dinesh
    [J]. RHEUMATOLOGY, 2018, 57 (05) : 813 - 817
  • [6] Incidence and prevalence of systemic sclerosis and systemic sclerosis with interstitial lung disease in the United States
    Fan, Yanni
    Bender, Shaun
    Shi, Weizhi
    Zoz, Donald
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (12) : 1539 - 1547
  • [7] Fennell P., 2020, ARTHRITIS RHEUMATOL, V72
  • [8] Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database
    Frantz, Camelia
    Huscher, Dorte
    Avouac, Jerome
    Hachulla, Eric
    Balbir-Gurrnan, Alexandra
    Riemekasten, Gabriela
    Siegert, Elise
    Lazzaroni, Maria-Grazia
    Carreira, Patricia E.
    Vettori, Serena
    Zanatta, Elisabetta
    Ullman, Susanne
    Czirjak, Laszlo
    Kowal-Bielecka, Otylia
    Distler, Oliver
    Matucci-Cerini, Marco
    Allanore, Yannick
    [J]. AUTOIMMUNITY REVIEWS, 2020, 19 (02)
  • [9] Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases
    Hernandez-Gonzalez, Fernanda
    Prieto-Gonzalez, Sergio
    Brito-Zeron, Pilar
    Cuerpo, Sandra
    Sanchez, Marcelo
    Ramirez, Jose
    Agusti, Carlos
    Lucena, Carmen Maria
    Paradela, Marina
    Grafia, Ignacio
    Espinosa, Gerard
    Sellares, Jacobo
    [J]. MEDICINE, 2020, 99 (04)
  • [10] The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements
    Hoffmann-Vold, Anna-Maria
    Maher, Toby M.
    Philpot, Edward E.
    Ashrafzadeh, Ali
    Barake, Rafic
    Barsotti, Simone
    Bruni, Cosimo
    Carducci, Paolo
    Carreira, Patricia E.
    Castellvi, Ivan
    Del Galdo, Francesco
    Distler, Joerg H. W.
    Foeldvari, Ivan
    Fraticelli, Paolo
    George, Peter M.
    Griffiths, Bridget
    Guillen-Del-Castillo, Alfredo
    Hamid, Abdul Monem
    Horvath, Rudolf
    Hughes, Michael
    Kreuter, Michael
    Moazedi-Fuerst, Florentine
    Olas, Jacek
    Paul, Suman
    Rotondo, Cinzia
    Rubio-Rivas, Manuel
    Seferian, Andrei
    Tomcik, Michal
    Uzunhan, Yurdagul
    Walker, Ulrich A.
    Wiesik-Szewczyk, Ewa
    Distler, Oliver
    [J]. LANCET RHEUMATOLOGY, 2020, 2 (02) : E71 - E83